New Indication for Velcade in Previously Untreated Myeloma

Oncology NEWS InternationalOncology NEWS International Vol 17 No 7
Volume 17
Issue 7

FDA has approved Millennium and Takeda’s Velcade (bortezomib) for previously untreated multiple myeloma.

FDA has approved Millennium and Takeda’s Velcade (bortezomib) for previously untreated multiple myeloma. “This comes as wonderful news for patients. The VISTA trial showed a 30% complete remission rate with bortezomib compared to 4% for the control arm. Importantly, patients treated with bortezomib also experienced a survival benefit,” said Paul Richardson, MD, senior investigator for the study and clinical director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. For a report on the VISTA study, see ONI March 2008, page 51.

Related Videos
Experts on multiple myeloma
Experts on multiple myeloma
Experts on MM
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma
Experts on multiple myeloma
Expert on MM
Related Content